NCT01407978已完成不适用
Tolerability and Immunogenicity Study of FLUVAL P H1N1 Monovalent Influenza Vaccine of Omninvest in Children and Adolescents
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 58
- 试验地点
- 2
- 主要终点
- Incidence of adverse events
研究概览
简要总结
This is a single-blind, reference drug controlled study to assess safety and tolerability of FLUVAL P H1N1 monovalent influenza vaccine (whole virus, inactivated, adjuvanted with alumn phosphate gel) containing 6 mcgHA per 0.5mL active ingredient in children and adolescents. To assess, as secondary objective, the efficacy (immunogenicity) of the vaccine by serology testing.
详细描述
Primary Objective:
- To assess tolerability/safety (incidence of adverse events 21-28 days following vaccination) of the study drug.
Secondary Objectives:
- To assess the efficacy (immunogenicity) of the study drug by serology testing of blood samples taken at Day 21-28 after immunization in groups and age groups.
- To assess long term (180-210 days following vaccination) tolerability/safety (incidence of adverse events) of the study drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 3 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Children aged 3 to 12 years, adolescents aged 12 to 18 years, both sexes;
- •Are in good health (as determined by vital signs and existing medical condition) or are in stable medical condition. Subjects will not be excluded with known adequately treated clinically significant organ or systemic diseases (e.g. asthma or diabetes)m such that, in the opinion of the investigator, the significance of the disease will not compromise the subject's participation in the study.
- •Female volunteers of childbearing potential with a negative result from the urine pregnancy test prior to vaccination who agrees to use an acceptable contraception method (includes implants, injectibles, combined oral contraceptives, effective intrauterine devices /IUDs/, sexual abstinence, or a vasectomized partner) or abstinence throughout the trial and not become pregnant for the duration of the study.
- •Capability of adolescent participants aged 12 to 18 years and the legitimate representative of all volunteers to understand and comply with planned study procedures;
- •Absence of existence of any exclusion criteria.
排除标准
- •Pregnancy or breast feeding or positive urine pregnancy test at baseline prior to vaccination;
- •Known allergy to eggs or other components of the vaccine (in particular mercury);
- •History of Guillain-Barré syndrome;
- •Active neoplasm (i.e. requiring any form of anti-neoplastic therapy);
- •Immunosuppressive therapy in the preceding 36 months;
- •Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids (local corticosteroid or corticosteroid nasal spray are permitted);
- •Immunoglobulin (or similar blood product) therapy within 3 months prior to vaccination;
- •Documented HIV, HBV or HCV infection;
- •Chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the immunoresponse;
- •Acute febrile respiratory illness within one week prior to vaccination;
- •Vaccine therapy within 4 weeks prior to vaccination;
- •Influenza vaccination within 6 months prior to vaccination;
- •Experimental drug therapy within 1 month prior to vaccination;
- •Past or current psychiatric disease of the volunteer or the legitimate representative that upon judgement of the investigator may have effect on the objective decision-making of the volunteer or the legitimate representative;
- •Alcohol or drug abuse of the participant or the legitimate representative.
结局指标
主要结局
Incidence of adverse events
时间窗: 21-28 days after vaccination
次要结局
- Post vaccination HI antibody titer(21-28 days after vaccination)
- Incidence of adverse events(180-210 days after vaccination)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza VaccineInfluenzaNCT00778297Fluart Innovative Vaccine Ltd, Hungary234
已完成
不适用
Tolerability and Immunogenicity of Fluval P Monovalent Influenza VaccineInfluenzaNCT01010893Fluart Innovative Vaccine Ltd, Hungary355
已完成
不适用
Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in ChildrenInfluenzaNCT01100294Fluart Innovative Vaccine Ltd, Hungary10
已完成
2 期
Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza VaccineInfluenza, HumanInfluenza Viral InfectionsVaccine ReactionInfluenzaInfection VaccinationNCT05869201St. Petersburg Research Institute of Vaccines and Sera450
已完成
3 期
Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older AdultsInfluenzaNCT00380211GlaxoSmithKline660